Cocrystal Pharma Completes Dosing in Phase 1b Norovirus Study for CDI-988; No Serious Adverse Events Reported
COCP sits 49% above its 52-week low of $0.76.
Summary
Cocrystal Pharma completed dosing in its Phase 1b norovirus study for CDI-988, reporting no serious adverse events and expecting preliminary efficacy results by early 2027.
Key Events · Product Development and Regulatory · COCP
-
Phase 1b Norovirus Study Dosing Completed
Cocrystal Pharma announced the last subject has been dosed in its Phase 1b norovirus challenge study (NCT07198139) evaluating CDI-988 as both a preventive and treatment for norovirus infections.
-
Positive Safety Profile
No serious adverse events have been reported to date in the study, building on previous Phase 1 data showing CDI-988 was safe and well tolerated.
-
Efficacy Results Expected
Preliminary efficacy results from the study are anticipated in late 2026 or early 2027, which will be crucial for further clinical advancement.
Analysis · COCP · Life Sciences
Cocrystal Pharma, a clinical-stage biotech with a recent going concern warning, announced a key operational milestone by completing patient dosing in its Phase 1b norovirus challenge study for CDI-988. This progress, coupled with no serious adverse events reported, is a positive development for the company's pipeline and future prospects. Preliminary efficacy results are anticipated in late 2026 or early 2027, which will be critical for the drug's advancement.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.1% of the 2014 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, COCP was trading at $1.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.7M. The 52-week trading range was $0.76 to $2.67. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.